Literature DB >> 35712441

Elective Neck Dissection Versus Therapeutic Neck Dissection in Clinically Node-Negative Early Stage Oral Cancer: A Meta-analysis of Randomized Controlled Trials.

Anshuman Kumar1, Suhani Ghai1, Shubhangi Mhaske2, Renu Singh3.   

Abstract

Introduction: Oral squamous cell carcinoma (OSCC) is characterized by a high risk of cervical lymph node metastasis; however, it is still not clear whether patients with early stage OSCC with clinical N0 neck should undergo elective neck dissection (END) at the time of primary tumor removal, or they should undergo a conservative approach of observation (OBS), with therapeutic neck dissection at the time of lymph nodal recurrence. We conducted a meta-analysis of randomized controlled trials (RCTs) that compared these two approaches.
Methods: PubMed and Scopus databases were searched for RCTs published in English language related to END and OBS in patients with early stage OSCC with clinical N0 neck. A meta-analysis was performed using random effects model with hazard ratio (HR) as the effect size for survival parameters and odds ratio (OR) as the effect size for lymph nodal recurrence.
Results: A total of 7 RCTs, comprising 1250 patients were included in the meta-analysis. Results of the meta-analyses showed that as compared to OBS approach, END could significantly improve overall survival (HR 0.67; 95% CI 0.53, 0.86) and disease-free survival (HR 0.64; 95% CI 0.46, 0.89), and significantly reduce lymph nodal recurrence (OR 0.28; 95% CI 0.12, 0.66). After correcting for heterogeneity, the disease specific survival was also found to be improved by the END approach (HR 0.53; 95% CI 0.29, 0.98).
Conclusion: The results of this meta-analysis suggest that elective neck dissection at the time of resection of the primary tumor not only leads to a reduced chance of nodal recurrence, but also confers a survival benefit in patients with clinically node-negative early stage oral cancer. © The Association of Oral and Maxillofacial Surgeons of India 2021.

Entities:  

Keywords:  Buccal mucosa cancer; Elective neck dissection; Lymph node recurrence; Oral cancer; Tongue cancer

Year:  2022        PMID: 35712441      PMCID: PMC9192853          DOI: 10.1007/s12663-021-01677-z

Source DB:  PubMed          Journal:  J Maxillofac Oral Surg        ISSN: 0972-8270


  40 in total

Review 1.  Management of the clinically N0 neck in early-stage oral squamous cell carcinoma (OSCC). An EACMFS position paper.

Authors:  Leandros V Vassiliou; Julio Acero; Aakshay Gulati; Frank Hölzle; Iain L Hutchison; Satheesh Prabhu; Sylvie Testelin; Klaus-Dietrich Wolff; Nicholas Kalavrezos
Journal:  J Craniomaxillofac Surg       Date:  2020-07-02       Impact factor: 2.078

2.  Elective neck dissection in T1/T2 oral squamous cell carcinoma with N0 neck: essential or not? A systematic review and meta-analysis.

Authors:  Samer Ahmed Ibrahim; Ahmed Nabil Abdelhamid Ahmed; Hisham Abdelaty Elsersy; Islam Mohammed Hussein Darahem
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-25       Impact factor: 2.503

3.  Elective neck dissection versus observation for early-stage oral squamous cell carcinoma: Systematic review and meta-analysis.

Authors:  L J Oh; K Phan; S W Kim; T H Low; R Gupta; J R Clark
Journal:  Oral Oncol       Date:  2020-03-31       Impact factor: 5.337

Review 4.  The diagnosis and treatment of oral cavity cancer.

Authors:  Klaus-Dietrich Wolff; Markus Follmann; Alexander Nast
Journal:  Dtsch Arztebl Int       Date:  2012-11-30       Impact factor: 5.594

5.  Clinical nodal stage is a significant predictor of outcome in patients with oral cavity squamous cell carcinoma and pathologically negative neck metastases: results of the international consortium for outcome research.

Authors:  M Amit; T C Yen; C T Liao; Y Binenbaum; P Chaturvedi; J P Agarwal; L P Kowalski; A Ebrahimi; J R Clark; C R Cernea; S J Brandao; M Kreppel; J Zöller; D Fliss; G Bachar; T Shpitzer; V A Bolzoni; P R Patel; S Jonnalagadda; K T Robbins; J P Shah; S G Patel; Ziv Gil
Journal:  Ann Surg Oncol       Date:  2013-06-18       Impact factor: 5.344

6.  Prognostic impact of perineural invasion in early stage oral tongue squamous cell carcinoma: Results from a prospective randomized trial.

Authors:  Xi Yang; Xuerui Tian; Kailiu Wu; Wei Liu; Siyi Li; Zhiyuan Zhang; Chenping Zhang
Journal:  Surg Oncol       Date:  2018-02-15       Impact factor: 3.279

7.  Neck nodal recurrence and survival of clinical T1-2 N0 oral squamous cell carcinoma in comparison of elective neck dissection versus observation: A meta-analysis.

Authors:  Hongshi Cai; Yue Zhu; Cheng Wang; Yadong Zhang; Jinsong Hou
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2019-11-05

8.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

Review 9.  Neck failure following pathologically node-negative neck dissection (pN0) in oral squamous cell carcinoma: a systematic review and meta-analysis.

Authors:  S Chegini; C Schilling; E S Walgama; K M Yu; K Thankappan; S Iyer; P Cariati; D Balasubramanian; A Kanatas; S Y Lai; M McGurk
Journal:  Br J Oral Maxillofac Surg       Date:  2021-04-15       Impact factor: 2.018

10.  Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.

Authors:  Iain L Hutchison; Fran Ridout; Sharon M Y Cheung; Allan Hackshaw; Neil Shah; Peter Hardee; Christian Surwald; Janavikulam Thiruchelvam; Leo Cheng; Tim K Mellor; Peter A Brennan; Andrew J Baldwin; Richard J Shaw; Wayne Halfpenny; Martin Danford; Simon Whitley; Graham Smith; Malcolm W Bailey; Bob Woodwards; Manu Patel; Joseph McManners; Chi-Hwa Chan; Andrew Burns; Prav Praveen; Andrew C Camilleri; Chris Avery; Graham Putnam; Keith Jones; Keith Webster; William P Smith; Colin Edge; Iain McVicar; Nick Grew; Stuart Hislop; Nicholas Kalavrezos; Ian C Martin
Journal:  Br J Cancer       Date:  2019-10-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.